or Try an Advanced Search...

    Technical Analysis for ROIV - Roivant Sciences Ltd.

    Grade Last Price % Change Price Change
    B 11.03 1.38% 0.15
    ROIV closed up 1.38 percent on Friday, April 26, 2024, on 42 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical ROIV trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Crossed Above 50 DMA Bullish 0.00%
    MACD Bullish Centerline Cross Bullish 0.00%
    MACD Bullish Signal Line Cross Bullish 0.00%
    200 DMA Support Bullish 1.38%
    Gapped Down Weakness 1.38%
    50 DMA Resistance Bearish 1.19%
    Fell Below 20 DMA Bearish 1.19%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.19%
    50 DMA Resistance Bearish 0.82%
    Older End-of-Day Signals for ROIV ...

       Recent Intraday Alerts

    Alert Time
    Up 2% about 16 hours ago
    60 Minute Opening Range Breakout about 17 hours ago
    60 Minute Opening Range Breakdown about 18 hours ago
    50 DMA Resistance about 18 hours ago
    Rose Above 20 DMA about 19 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ROIV Chart by TradingView
    Basic chart:

    Profile

    Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Immunology Antibodies Autoimmune Disease Inflammation Monoclonal Antibodies Psoriasis Ulcerative Colitis Abdominal Pain Atopic Dermatitis Crohn's Disease Treatment Of Psoriasis

    Is ROIV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 24 Roivant Sciences: Cashing In On Vants And Ventures
    Apr 2 Roivant announces $1.5B share buyback, positive Phase 2 data
    Apr 2 Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
    Mar 27 Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck
    Mar 26 Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
    Mar 18 Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
    Feb 14 The Analyst Landscape: 4 Takes On Roivant Sciences
    Feb 14 Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations
    Feb 13 Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript
    Feb 13 Roivant Sciences GAAP EPS of $6.03 beats by $5.54, revenue of $37.14M beats by $7.32M
    See more ROIV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.24
    52 Week Low 8.06
    Average Volume 7,451,458
    200-Day Moving Average 10.64
    50-Day Moving Average 10.94
    20-Day Moving Average 10.98
    10-Day Moving Average 10.72
    Average True Range 0.37
    RSI (14) 54.13
    ADX 14.44
    +DI 26.21
    -DI 23.09
    Chandelier Exit (Long, 3 ATRs) 10.68
    Chandelier Exit (Short, 3 ATRs) 11.27
    Upper Bollinger Bands 11.80
    Lower Bollinger Band 10.16
    Percent B (%b) 0.53
    BandWidth 14.89
    MACD Line 0.01
    MACD Signal Line 0.00
    MACD Histogram 0.0039
    Fundamentals Value
    Market Cap 8.87 Billion
    Num Shares 804 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -7.50
    Price-to-Sales 84.25
    Price-to-Book 8.96
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.38
    Resistance 3 (R3) 11.37 11.24 11.32
    Resistance 2 (R2) 11.24 11.15 11.25 11.30
    Resistance 1 (R1) 11.14 11.09 11.19 11.15 11.28
    Pivot Point 11.01 11.01 11.03 11.01 11.01
    Support 1 (S1) 10.90 10.92 10.95 10.91 10.78
    Support 2 (S2) 10.77 10.86 10.78 10.76
    Support 3 (S3) 10.67 10.77 10.74
    Support 4 (S4) 10.68